Comparative Pharmacology
Head-to-head clinical analysis: LUCEMYRA versus LUMIFY PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUCEMYRA versus LUMIFY PRESERVATIVE FREE.
LUCEMYRA vs LUMIFY PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUCEMYRA (lofexidine) is a central alpha-2 adrenergic agonist that reduces the release of norepinephrine in the brain, thereby alleviating opioid withdrawal symptoms.
Selective alpha-1 adrenergic receptor agonist; causes vasoconstriction of conjunctival blood vessels, reducing redness.
18 mg orally 5-6 times daily (maximum 108 mg/day) for 7-14 days then tapered over 4-6 weeks.
1 drop in each affected eye every 6-8 hours as needed, ophthalmic route.
None Documented
None Documented
Terminal half-life approximately 5-6 hours; no clinically significant accumulation with twice-daily dosing.
Terminal elimination half-life is approximately 2-3 hours. Clinical context: Allows for twice-daily dosing for sustained intraocular pressure reduction; steady-state achieved within 2 days.
Renal: 63% as unchanged drug; fecal: 27% (mostly unchanged); biliary: minimal (<5%).
Primarily renal excretion of unchanged drug (approx. 60-80%) and metabolites (glucuronide conjugates). Biliary/fecal elimination accounts for <10%.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist